Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

Cardinal Health's growth faces challenges from tariff risks, regulatory uncertainties, and competitive pressures. Learn more ...

Cardinal Health’s (CAH) robust growth in pharmaceutical distribution and oncology drugs positions it to capitalize on ...

SAN ANTONIO, June 03, 2025--bioAffinity Technologies' collaboration with Cardinal Health's logistics arm ensures CyPath® Lung ...

Cardinal Health Inc. (NYSE:CAH) announced the US launch of its new Kendall DL Multi System. This multi-parameter, ...

Analysts are intrested in these 5 stocks: ( ($CAH) ), ( ($DG) ), ( ($SNOW) ), ( ($CEG) ) and ( ($CRWD) ). Here is a breakdown of their recent ...

Fintel reports that on June 3, 2025, Wells Fargo upgraded their outlook for Cardinal Health (NYSE:CAH) from Equal-Weight to ...

Wells Fargo on Tuesday upgraded medical distributors Cardinal Health (NYSE:CAH) and Cencora (NYSE:COR) to Overweight from Equal Weight, citing a strong industry backdrop as a major reason for both ...

In a report released today, Steven Valiquette from Mizuho Securities maintained a Buy rating on Cardinal Health (CAH – Research Report), with a price target of $161.00. The comp ...

Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), has entered into a distribution services agreement with Cardinal Health (NYSE:CAH). This ...

Wells Fargo analysts upgraded Cardinal Health, Inc. (NYSE:CAH)’s stock to “Overweight” from “Equal Weight,” lifting the price ...